Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

JULIO C CHAVEZ

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1750543948
CMS profile
1011346
Location
TAMPA, FL

General Payments · PY2018–2024

$326,090.67

  • Reported across 284 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$50,500.01

46 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Genmab U.S., Inc. $12,994.04 12
Gilead Sciences, Inc. $10,124.18 2
E.R. Squibb & Sons, L.L.C. $6,671.00 3
NOVARTIS PHARMACEUTICALS CORPORATION $6,044.07 9
Acerta Pharma LLC $5,223.80 6
Lilly USA, LLC $5,000.00 3
ABBVIE INC. $2,233.96 6
Genentech USA, Inc. $1,914.23 2
Kite Pharma, Inc. $250.00 2
Legend Biotech USA Inc. $44.73 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $43,395.28 50
PY2019 $58,688.16 47
PY2020 $48,990.40 27
PY2021 $29,930.50 28
PY2022 $34,392.14 34
PY2023 $60,194.18 52
PY2024 $50,500.01 46

Payment records · PY2024 (46)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $675.00 04/30/2024 Consulting Fee Undisputed 01/23/2026 1103132787 CMS
ABBVIE INC. $675.00 07/26/2024 Consulting Fee Undisputed 01/23/2026 1103132789 CMS
ABBVIE INC. $288.22 11/15/2024 Travel and Lodging Undisputed 01/23/2026 1104180268 CMS
ABBVIE INC. $50.00 11/16/2024 Food and Beverage Undisputed 01/23/2026 1103449448 CMS
ABBVIE INC. $10.00 11/16/2024 Food and Beverage Undisputed 01/23/2026 1103449450 CMS
ABBVIE INC. $535.74 11/16/2024 Travel and Lodging Undisputed 01/23/2026 1104180270 CMS
AstraZeneca Pharmaceuticals LP $563.21 02/28/2024 Travel and Lodging Undisputed 01/23/2026 1105306589 CMS
AstraZeneca Pharmaceuticals LP $3,000.00 03/14/2024 Compensation for serving as faculty or as a speaker for a medical education program Undisputed 01/23/2026 1105429596 CMS
AstraZeneca Pharmaceuticals LP $160.26 03/30/2024 Food and Beverage Undisputed 01/23/2026 1104348118 CMS
AstraZeneca Pharmaceuticals LP $91.33 03/30/2024 Travel and Lodging Undisputed 01/23/2026 1104735983 CMS
AstraZeneca Pharmaceuticals LP $209.00 03/30/2024 Travel and Lodging Undisputed 01/23/2026 1105277357 CMS
AstraZeneca Pharmaceuticals LP $1,200.00 04/18/2024 Compensation for serving as faculty or as a speaker for a medical education program Undisputed 01/23/2026 1105440555 CMS
E.R. Squibb & Sons, L.L.C. $2,076.00 01/16/2024 Consulting Fee Undisputed 01/23/2026 1101381708 CMS
E.R. Squibb & Sons, L.L.C. $1,730.00 03/14/2024 Consulting Fee Undisputed 01/23/2026 1101381726 CMS
E.R. Squibb & Sons, L.L.C. $2,865.00 12/12/2024 Consulting Fee Undisputed 01/23/2026 1101381802 CMS
Genentech USA, Inc. $1,875.00 11/11/2024 Consulting Fee Undisputed 01/23/2026 1133042753 CMS
Genentech USA, Inc. $39.23 12/06/2024 Food and Beverage Undisputed 01/23/2026 1133042757 CMS
Genmab U.S., Inc. $32.03 02/23/2024 Food and Beverage Undisputed 01/23/2026 1126828332 CMS
Genmab U.S., Inc. $258.77 04/19/2024 Travel and Lodging Undisputed 01/23/2026 1126828334 CMS
Genmab U.S., Inc. $582.21 04/19/2024 Travel and Lodging Undisputed 01/23/2026 1126828336 CMS
Genmab U.S., Inc. $33.54 04/20/2024 Food and Beverage Undisputed 01/23/2026 1126828340 CMS
Genmab U.S., Inc. $47.92 04/20/2024 Food and Beverage Undisputed 01/23/2026 1126828342 CMS
Genmab U.S., Inc. $23.96 04/20/2024 Food and Beverage Undisputed 01/23/2026 1126828344 CMS
Genmab U.S., Inc. $3,750.00 05/23/2024 Consulting Fee Undisputed 01/23/2026 1126828338 CMS
Genmab U.S., Inc. $138.02 08/20/2024 Food and Beverage Undisputed 01/23/2026 1126828346 CMS
Genmab U.S., Inc. $752.59 10/22/2024 Travel and Lodging Undisputed 01/23/2026 1126828350 CMS
Genmab U.S., Inc. $5,075.00 10/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1126828352 CMS
Genmab U.S., Inc. $125.00 11/01/2024 Food and Beverage Undisputed 01/23/2026 1126828354 CMS
Genmab U.S., Inc. $2,175.00 11/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1126828348 CMS
Gilead Sciences, Inc. $124.18 01/20/2024 Food and Beverage Undisputed 01/23/2026 1133830253 CMS
Gilead Sciences, Inc. $10,000.00 08/07/2024 Consulting Fee Undisputed 01/23/2026 1133600001 CMS
Kite Pharma, Inc. $125.00 03/06/2024 Food and Beverage Undisputed 01/23/2026 1128611317 CMS
Kite Pharma, Inc. $125.00 12/07/2024 Food and Beverage Undisputed 01/23/2026 1128611327 CMS
Legend Biotech USA Inc. $44.73 10/26/2024 Food and Beverage Undisputed 01/23/2026 1131691918 CMS
Lilly USA, LLC $1,800.00 02/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135100796 CMS
Lilly USA, LLC $1,600.00 10/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135092517 CMS
Lilly USA, LLC $1,600.00 11/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1135111856 CMS
Novartis Pharmaceuticals Corporation $130.72 05/16/2024 Food and Beverage Undisputed 01/23/2026 1086617841 CMS
Novartis Pharmaceuticals Corporation $126.78 05/16/2024 Food and Beverage Undisputed 01/23/2026 1086617843 CMS
Novartis Pharmaceuticals Corporation $199.48 05/30/2024 Travel and Lodging Undisputed 01/23/2026 1086617837 CMS
Novartis Pharmaceuticals Corporation $191.15 05/31/2024 Travel and Lodging Undisputed 01/23/2026 1086617839 CMS
Novartis Pharmaceuticals Corporation $3,037.50 05/31/2024 Consulting Fee Undisputed 01/23/2026 1086617857 CMS
Novartis Pharmaceuticals Corporation $90.00 05/31/2024 Food and Beverage Undisputed 01/23/2026 1086617859 CMS
Novartis Pharmaceuticals Corporation $123.78 10/23/2024 Food and Beverage Undisputed 01/23/2026 1086617867 CMS
Novartis Pharmaceuticals Corporation $119.66 12/06/2024 Food and Beverage Undisputed 01/23/2026 1086617873 CMS
Novartis Pharmaceuticals Corporation $2,025.00 12/06/2024 Consulting Fee Undisputed 01/23/2026 1086617875 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.